PDABs Action Center

Quick Links: Videos | Blogs | Infographics | Policy Papers | Webinars | Other Resources

---

The Community Access National Network (CANN) Prescription Drug Advisory Board Response Project for People Living with HIV is designed to provide a national, state-by-state, patient-facing resource on policies, programs, activities, and news on recent state-level efforts, including Prescription Drug Advisory Boards (PDABs), to set drug prices and reimbursement rates, and could affect providers, patients, and access to care and medication. While various public and private evaluative actors already engage in negotiating medication list-prices and reimbursement rates, PDABs pose the potential to undermine determinative factors, such as treatment guidelines and efficacy and tolerability as demonstrated in non-inferiority studies, in favor of an arbitrary financial factor. Most notably, the financial factor PDABs seek to determine do not necessarily have a direct relationship with patient out-of-pocket costs. As such there is no sufficient evidence to support the notion that reduction in list-prices or reimbursement rates benefit patients. To the contrary, due to various rebate and public health funding schemes which may be dependent on revenues generated from these rebate models, arbitrary price-setting policies risk negatively impacting patient access to care and necessarily disrupt the provider-patient relationship.

CLICK HERE to join our national listserv and receive the latest information on PDABs.

Read our additional perspectives about PDABs:

• Prescription Drug Advisory Boards: What They Are and Why They Matter to Patients - (July 10, 2023)
• Prescription Drug Advisory Boards: Who is Impacted and How to get Involved - (September 18, 2023)
• States Push PDABs Despite Warning Signs, Patient Concerns - (January 29, 2024)
• Prescription Drug Affordability Boards: A Threat to Ending the HIV Epidemic? - (July 1, 2024)
• Prescription Drug Affordability Boards and the ADA: A Potential Conflict? - (July 29, 2024)

Download our educational infographics about PDABs:

• Prescription Drug Advisory Boards: What They Are and Why They Matter to Patients - (October 31, 2023)
• Prescription Drug Advisory Boards: Where Are They and Why and How to Influence Them: Part 1 - (October 31, 2023)
• Prescription Drug Advisory Boards: Where Are They and Why and How to Influence Them: Part 2 - (November 20, 2023)
• Prescription Drug Affordability Boards: A Threat to Ending the HIV Epidemic? - (June 18, 2024)
• Prescription Drug Affordability Boards and the ADA: A Potential Conflict? - (July 29, 2024)

Watch our animated videos about PDABs:

• [Video] PDABs Price Control Wolves in Sheep's Clothing - (January 18, 2024)

Watch our educational webinars about PDABs:

• [Video] Prescription Drug Affordability Boards: What They Are and How They Impact Patients - (November 1, 2023)
  • Download Slides

Download our policy papers about PDABs:

• Prescription Drug Advisory Boards: Policy Paper - (January 18, 2024)
• Impact of State Prescription Drug Affordability Boards on Access to Medications for Potentially Disabling Conditions - (July, 2024)
  • Master Drug List - All States (as of July 2024)

Click on the following links to other resources about PDABs:

• Janssen Pharmaceutical Companies of Johnson & Johnson: Influence of Prescription Drug Affordability Boards and Upper Payment Limits on the State Drug Pricing Ecosystem - (2024)
• Partnership to Fight Chronic Disease: Health Plans Predict: Implementing Upper Payment Limits May Alter Formularies And Benefit Design But Won’t Reduce Patient Costs - (2024)
• Partnership to Fight Chronic Disease: Insurer Perspectives on PDABs - (2024)
• PlusInc: COST CONTAINMENT vs. CARE EQUALITY: How Health Disparities Among Chronic Health Conditions & Rare Diseases are Fueled by Payor-Driven Barriers - (2024)

For additional information about Prescription Drug Advisory Boards, please contact us at: info@tiicann.org.